MRG 106

Drug Profile

MRG 106

Alternative Names: MRG 106

Latest Information Update: 16 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator miRagen Therapeutics
  • Class Antifungals; Antineoplastics
  • Mechanism of Action MicroRNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma; Mycosis fungoides
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cutaneous T cell lymphoma
  • Preclinical Amyotrophic lateral sclerosis

Most Recent Events

  • 11 Aug 2017 Updated efficacy data from a phase I trial in Cutaneous T-cell lymphoma released by miRagen Therapeutics
  • 11 Aug 2017 Following a discussion with the US FDA in June 2017, miRagen Therapeutics plans phase I trial expansion to include patients with adult T-cell leukaemia/lymphoma, Diffuse large B-cell lymphoma and chronic lymphocytic leukaemia by 2H 2017
  • 11 Aug 2017 miRagen Therapeutics plans a phase II trial in Cutaneous T-cell lymphoma (including, Mycosis fungoides) and Non-Hodgkin’s lymphoma by second-half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top